Zobrazeno 1 - 10
of 39
pro vyhledávání: '"NA Dobbs"'
Autor:
Chris Twelves, C Cruickshanka, Michael Richards, NA Dobbs, Walter M Gregory, Robert D. Rubens
Publikováno v:
European Journal of Cancer. 39:580-586
This study aimed to develop an epirubicin dose modification scheme in women with breast cancer and liver dysfunction. We first identified target areas under the concentration-time curve (AUCs) of 2400 and 1600 ng/ml.h from pharmacokinetic studies in
Autor:
C. J. Twelves, Amanda-Jane Ramirez, Michael Richards, K E Towlson, MA Lawrence, Robert D. Rubens, M Summerhayes, NA Dobbs
Publikováno v:
British Journal of Cancer
Iododoxorubicin 80 mg m-2 i.v. was given 3 weekly for a maximum of six cycles as first-line chemotherapy to 14 evaluable women with metastatic breast cancer. The response rate was 14% (95% confidence intervals 4-40%); median time to progression was 3
Autor:
M A Richards, M.A. Smith, P E Graves, M. Lowry, C. J. Twelves, D.A. Porter, Robert D. Rubens, NA Dobbs
Publikováno v:
British Journal of Cancer
We have studied the metabolism of 31P-containing metabolites of post-menopausal breast cancers in vivo using magnetic resonance spectroscopy (MRS) and a 5.5 cm surface coil. Spectra were acquired from 23 diameter. The spectra of the 19 previously unt
Autor:
Philip J. Johnson, Paulo Rizzi, Julie D. Warwick, C. J. Twelves, Elizabeth M. Metivier, Roger Williams, NA Dobbs
Publikováno v:
Cancer Chemotherapy and Pharmacology. 34:405-410
The pharmacokinetics and clinical activity of epirubicin were investigated in 16 patients with hepatocellular carcinoma (HCC) who received epirubicin at 75 mg/m2; the drug was given intravenously to 7 patients and via the hepatic artery to 9 patients
Autor:
Philip J. Johnson, R. Williams, NA Dobbs, Peter Harper, C. Kalayci, M. C. Aldous, EM Metivier
Publikováno v:
British Journal of Cancer
A standard dose of Adriamycin (60 mg m-2) was administered to 30 patients with inoperable hepatocellular carcinoma, 16 of whom were hyperbilirubinaemic (18-37 mumol l-1). The hyperbilirubinaemic patients experienced marked myelosuppression, but only
Publikováno v:
Cancer chemotherapy and pharmacology. 42(3)
We studied variability in doxorubicin pharmacokinetics in 24 patients with abnormal liver biochemistry tests. Blood samples were collected after the first cycle of single-agent doxorubicin given as an i.v. bolus and plasma levels were measured by hig
Publikováno v:
Cancer chemotherapy and pharmacology. 36(6)
We studied the variability in doxorubicin pharmacokinetics in 27 patients, all of whom had normal liver biochemistry tests. Blood samples were collected after the first cycle of single-agent doxorubicin given as an i.v. bolus and plasma levels were m
Autor:
Peter Canney, AL Stewart, Alison Curnow, NA Dobbs, Robert D. Rubens, C. J. Twelves, C.J. Tyrrell, Robert E. Coleman
Publikováno v:
British Journal of Cancer
Thirty-four evaluable patients were treated with vinorelbine, a novel, semisynthetic vinca alkaloid, as first-line chemotherapy for advanced breast cancer. They received vinorelbine 25 mg m-2 i.v. given weekly for a maximum of 16 cycles. Two patients
Publikováno v:
The British journal of radiology. 67(793)
We have studied the metabolism of compounds containing 31P in normal breast using magnetic resonance spectroscopy (MRS). Spectra were acquired from non-lactating pre-menopausal breast (n = 14 women), lactating breast (n = 8) and post-menopausal breas
Autor:
C. J. Twelves, NA Dobbs
Publikováno v:
Journal of chromatography. 572(1-2)
A sensitive and rapid method for measuring epidoxorubicin and its six metabolites by high-performance liquid chromatography using an advanced automated sample processor is described. Plasma samples (1 ml) were extracted using C2 cassettes, and revers